Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

  • In Science
  • 2019-02-12 14:12:02Z
  • By Zacks Equity Research

Merck & Co., Inc. MRK announced that the FDA has granted a priority review to yet another supplemental biologics license application (sBLA) for its PD-L1 inhibitor, Keytruda. With the latest sBLA filing, Merck is looking to get Keytruda approved for the first-line treatment of patients suffering recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), both as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy.

With the FDA granting a priority review to the sBLA, a decision is expected on Jun 10, 2019. The approval will help Merck gain access to a broader patient population and boost sales for its blockbuster drug.

The sBLA was based on data from the phase III KEYNOTE-048 study wherein Keytruda as a monotherapy and also combined with chemotherapy demonstrated a significant improvement in overall survival (OS) as compared to the standard of care in the given patients, whose tumors expressed PD-L1 with CPS(combined proportion score)≥20 and CPS≥1.

Shares of Merck have surged 39.8% in the past year, outperforming the industry's increase of 7.1%.

Keytruda is already approved for many types of cancers and treatment settings including lung cancer, melanoma, head and neck cancer, classical Hodgkin's lymphoma and bladder cancer.

In a very short span of time, Keytruda has become the largest product in Merck's portfolio. The drug generated sales of $7.17 billion in 2018, reflecting a massive 88% surge year over year. Sales were driven by the launch of new indications globally. Keytruda sales are particularly gaining from a strong momentum in first-line lung cancer indication as it is the only anti-PD-1 medicine approved in first-line setting.

The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in above 900 studies including 400 plus combination programs. Merck is collaborating with several companies, namely Amgen AMGN, Incyte INCY, Glaxo GSK and Pfizer, separately, for the evaluation of Keytruda in combination with other regimes.

Zacks Rank

Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Best Stock-Picking Strategy

It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.

How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.

Free - See the Stocks It Turned Up for Today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline plc (GSK) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

Incyte Corporation (INCY) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

More Related News

Pfizer, Merck Tumble as Health-Care Rout Spreads to Biopharma
Pfizer, Merck Tumble as Health-Care Rout Spreads to Biopharma

Pfizer Inc. and Merck & Co. are among companies bearing the brunt of Thursday's sell-off, with each down more than 2 percent at their lowest points. "Clearly, huge stock impacts to HCA and managed care can't be ignored and 'collateral damage' to sub-sectors like biopharma in the following days are reflective

3 Top Healthcare Stocks to Buy in April
3 Top Healthcare Stocks to Buy in April

GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.

Why J.B. Hunt, Bank of America, and Boston Scientific Slumped Today
Why J.B. Hunt, Bank of America, and Boston Scientific Slumped Today

These three stocks fell as the broader market climbed.

FDA orders transvaginal surgical mesh pulled from market
FDA orders transvaginal surgical mesh pulled from market

The U.S. Food and Drug Administration on Tuesday ordered makers of transvaginal surgical mesh implants to immediately stop their sale and distribution in the United States, the latest action by the agency to tackle safety issues related to the devices. The FDA said Boston Scientific Corp and Coloplast A/S did not demonstrate a reasonable assurance of safety and effectiveness of these devices in their premarket applications. The companies will have 10 days to submit their plan to withdraw these products from the market, the FDA said in a statement

The FDA's New Sugar Label Could Seriously Reduce Heart Disease and Diabetes-And Boost Longevity

A new study from Tufts University finds just how beneficial an added sugar label can be for our health and our wallets.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Science

Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.